{
    "ticker": "EXEL",
    "name": "Exelixis, Inc.",
    "description": "Exelixis, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for cancer. Founded in 1995 and headquartered in Alameda, California, Exelixis has made significant strides in advancing treatments that improve patient outcomes and enhance the quality of life for those affected by cancer. The company's lead product, cabozantinib, is a multi-tyrosine kinase inhibitor that has been approved for the treatment of various types of cancer, including renal cell carcinoma and hepatocellular carcinoma. Exelixis continues to pursue a robust pipeline of drug candidates that target significant unmet medical needs, leveraging its expertise in cancer biology and drug discovery. The company is dedicated to advancing precision medicine and enhancing patient care through its innovative research and development efforts. With a commitment to collaboration, Exelixis partners with leading academic institutions and biopharmaceutical companies to accelerate the development of new therapies. The company's mission is to help patients live longer and healthier lives through transformative cancer therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Alameda, California, USA",
    "founded": "1995",
    "website": "https://www.exelixis.com",
    "ceo": "Michael M. Morrissey",
    "social_media": {
        "twitter": "https://twitter.com/exelixis",
        "linkedin": "https://www.linkedin.com/company/exelixis/"
    },
    "investor_relations": "https://ir.exelixis.com",
    "key_executives": [
        {
            "name": "Michael M. Morrissey",
            "position": "CEO"
        },
        {
            "name": "Peter A. Lamb",
            "position": "CBO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "Cabozantinib (Cabometyx, Cometriq)"
            ]
        },
        {
            "category": "Pipeline Products",
            "products": [
                "XL092",
                "XL114"
            ]
        }
    ],
    "seo": {
        "meta_title": "Exelixis, Inc. | Innovative Cancer Therapies",
        "meta_description": "Learn about Exelixis, Inc., a biotechnology company dedicated to developing innovative therapies for cancer treatment. Explore our products and pipeline.",
        "keywords": [
            "Exelixis",
            "Cancer Therapy",
            "Biotechnology",
            "Cabozantinib",
            "Oncology",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does Exelixis focus on?",
            "answer": "Exelixis focuses on the development and commercialization of innovative therapies for cancer."
        },
        {
            "question": "What is Exelixis' lead product?",
            "answer": "Exelixis' lead product is cabozantinib, used for the treatment of various cancers."
        },
        {
            "question": "Where is Exelixis headquartered?",
            "answer": "Exelixis is headquartered in Alameda, California, USA."
        },
        {
            "question": "When was Exelixis founded?",
            "answer": "Exelixis was founded in 1995."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "BMY",
        "MRNA"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "ABBV",
        "BIIB"
    ]
}